XML 38 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Goodwill and Intangible Assets, Net
12 Months Ended
Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net
Goodwill and Intangible Assets, Net
The changes in the carrying amount of goodwill for the years ended December 31, 2017 and 2016, are as follows:
 
2017
 
2016
Beginning balance
$
157,175

 
$
165,169

Acquisitions
4,850

 

Impairment
(13,823
)
 

Foreign currency translation adjustments
5,087

 
(7,994
)
Ending balance
$
153,289

 
$
157,175


For the year ended December 31, 2017, the Company recorded a $13,823 goodwill impairment charge, which primarily relates to AquaBounty. During the Company's annual goodwill impairment test, the Company determined, based on the price per share received by AquaBounty in its recent underwritten public offering (Note 22), it was more-likely-than-not that the fair value of the AquaBounty reporting unit was less than its carrying amount. As a result, the Company compared the carrying amount of the AquaBounty reporting unit to the fair value and determined the carrying amount exceeded the fair value resulting in a $13,001 goodwill impairment charge for the excess carrying value. The Company did not recognize any goodwill impairment charges during the years ended December 31, 2016 or 2015, and there were no accumulated impairment charges as of December 31, 2016.
Intangible assets consist of the following as of December 31, 2017: 
 
Weighted Average Useful Life (Years)
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, developed technologies and know-how
15.9
 
$
263,615

 
$
(44,954
)
 
$
218,661

Customer relationships
6.5
 
10,700

 
(6,383
)
 
4,317

Trademarks
9.3
 
6,800

 
(2,567
)
 
4,233

In-process research and development
 
 
5,666

 

 
5,666

Total
 
 
$
286,781

 
$
(53,904
)
 
$
232,877


Intangible assets consist of the following as of December 31, 2016: 
 
Gross Carrying Amount
 
Accumulated Amortization
 
Net
Patents, developed technologies and know-how
$
236,401

 
$
(29,748
)
 
$
206,653

Customer relationships
10,700

 
(4,672
)
 
6,028

Trademarks
6,800

 
(1,792
)
 
5,008

Covenant not to compete
370

 
(339
)
 
31

In-process research and development
7,895

 

 
7,895

Total
$
262,166

 
$
(36,551
)
 
$
225,615


The balance of in-process research and development includes certain in-process research and development technology acquired in the Company's acquisition of Oxitec in September 2015, and amortization will begin once certain regulatory approvals have been obtained for the in-process programs. In 2017, the Company decided to forgo further development for certain of its in-process research and development assets and, as a result, recorded an impairment charge of $2,950.
Amortization expense was $19,194, $15,185 and $9,871 for the years ended December 31, 2017, 2016 and 2015, respectively. Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:
2018
$
19,258

2019
18,935

2020
18,833

2021
18,645

2022
17,646

Thereafter
133,894

Total
$
227,211